^
Association details:
| Biomarker: | HMGA1 deletion+ JAK2 V617F |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HMGA1 Chromatin Regulators Drive Progression in Myeloproliferative Neoplasms through Epigenetic Rewiring to Induce Networks Involved in GATA2 and Proliferation
Published date:
12/24/2021
Excerpt:
HMGA1 depletion enhances responses to the JAK/STAT Inhibitor, ruxolitinib, delaying leukemic engraftment and prolonging survival in murine models of JAK2V617F MPN-AML.
DOI:
10.1182/blood-2021-144712
